Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RLGLP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Omalizumab-alpha-amanitin conjugate 14
|
|||||
| Synonyms |
Omalizumab alpha-amanitin conjugate 14
Click to Show/Hide
|
|||||
| Organization |
Heidelberg Pharma AG
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Pancreatic ductal adenocarcinoma [ICD11:2C10]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Omalizumab
|
Antibody Info | ||||
| Antigen Name |
High affinity immunoglobulin epsilon receptor subunit alpha (FCER1A)
|
Antigen Info | ||||
| Payload Name |
Alpha-amanitin
|
Payload Info | ||||
| Therapeutic Target |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
|
Target Info | ||||
| Linker Name |
Omalizumab-alpha-amanitin conjugate 14 linker
|
|||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.